Revvity, Inc. (ex Perkinelmer, Inc.) Strengths, Domain Expertise, and Key Differentiators
Revvity Signals Software offers a comprehensive suite of cloud-native, AI-enhanced scientific informatics solutions designed to streamline data management, facilitate collaboration, and accelerate innovation across pharmaceutical, biotechnology, chemical, and materials research sectors. Its flagship platform, the Signals Research Suite, integrates tools like ChemDraw, Signals Notebook, and Spotfire to support the entire R&D lifecycle—from data capture and analysis to decision-making—empowering scientists to drive life-changing breakthroughs.
Following its rebranding from PerkinElmer in 2023, Revvity has intensified its focus on life sciences and diagnostics, investing in advanced software platforms and expanding its global reach to over 190 countries. Meanwhile, PerkinElmer continues to provide analytical instruments, services, and solutions across diagnostics, life sciences, and applied markets, supporting customers in environmental analysis, food safety, and industrial applications worldwide.
Revvity, Inc. (ex Perkinelmer, Inc.) Recent Developments
In April 2025, Revvity's informatics division, Revvity Signals Software, launched its Signals OneTM, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities and fosters collaboration in multidisciplinary workflows.
Revvity, Inc. (ex Perkinelmer, Inc.) Mergers and Acquisitions (M&A) Activities
In 2022, PerkinElmer underwent a split, leading to the divestiture of one segment encompassing its applied, food, and enterprise services businesses. This section was acquired by the private equity firm New Mountain Capital for $2.45 billion, resulting in its transition to private status while retaining the PerkinElmer name. Simultaneously, the remaining part, housing the life sciences and diagnostics businesses, remained publicly traded but necessitated a rebranding. In 2023, it was unveiled as Revvity, Inc. In May 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.
Revvity, Inc. (ex Perkinelmer, Inc.) Customers in ARTW Customer Database
Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying Revvity, Inc. (ex Perkinelmer, Inc.) applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of Revvity, Inc. (ex Perkinelmer, Inc.) and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified Signals One, ChemDraw, Spotfire Visual Analytics, Signals Clinical, signalsNotebook customers.
Revvity, Inc. (ex Perkinelmer, Inc.) Overview
77 4th Avenue
Waltham, MA, 2451, United States
1 781-663-6900
https://www.revvity.com/
Ownership: - NYSE: RVTY
Number of Employees: 11000
Functional Markets: Analytics and BI, Collaboration, ERP Services and Operations, PLM,
Key Verticals: Healthcare, Life Sciences,
Revvity, Inc. (ex Perkinelmer, Inc.) Key Enterprise and Cloud Applications
Signals One, ChemDraw, Spotfire Visual Analytics, Signals Clinical, signalsNotebook
Revvity, Inc. (ex Perkinelmer, Inc.) Revenues, $M:
| Type/Year | 2023 | 2024 | YoY Growth, % |
|---|---|---|---|
| Total Revenues, $M | Subscribe | Subscribe | Subscribe |
| Enterprise Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
| Cloud Applications Revenues, $M | Subscribe | Subscribe | Subscribe |
* Enterprise Applications Revenues = License + Support & Maintenance + SaaS
** All revenue figures are estimates based on public records, Cloud and Non-Cloud business models in Apps Run The World's vendor database, and annual survey results including vendor feedback.
Revvity, Inc. (ex Perkinelmer, Inc.) Revenue Breakdown By Type, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Revenues By Functional Markets, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Revenues By Verticals, $M:
Revvity, Inc. (ex Perkinelmer, Inc.) Revenues By Region, $M
| Region | % of Total Revenues | 2024 Total Revenues, $M | 2024 Enterprise Applications Revenues, $M | 2024 Cloud Applications Revenues, $M |
|---|---|---|---|---|
| Americas | Subscribe | Subscribe | Subscribe | Subscribe |
| EMEA | Subscribe | Subscribe | Subscribe | Subscribe |
| APAC | Subscribe | Subscribe | Subscribe | Subscribe |
| Total | Subscribe | Subscribe | Subscribe | Subscribe |
Revvity, Inc. (ex Perkinelmer, Inc.) Direct vs Indirect sales
| Type | Direct Sales | Indirect Sales | Total |
|---|---|---|---|
| Type % | Subscribe | Subscribe | Subscribe |
| Revenues, $M | Subscribe | Subscribe | Subscribe |
Revvity, Inc. (ex Perkinelmer, Inc.) Customers - Breakdown by Geo, Size, Vertical and Product
List of Verified Revvity, Inc. (ex Perkinelmer, Inc.) Customers
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Customers: 4000
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Enterprise Applications Customers: x
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Cloud Customers: x
No. of Revvity, Inc. (ex Perkinelmer, Inc.) Cloud Subscribers: 1 million
PerkinElmer's customer base has 4000+ worldwide customers and 1 million worldwide users, encompassing a diverse range of entities, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies.
Notable among the company's customers are organizations such as 4SC AG, Aarhus Universitet, Abraxis BioScience, Academia Sinica, Acadia Pharmaceuticals AB, Aceto Corporation, Achaogen, Inc., Achillion Pharmaceuticals, Acraf SpA, Acucela, Inc., Addex, Adesis Inc, Adherex Technologies Inc., Adolor Corporation, Advinus Therapeutics Pvt Ltd, AGES, Air Force Technical Applications Center, Air Products, Akzo Nobel NV, Alantos Pharmaceuticals, Albany College of Pharmacy, and Albany Molecular Research, Inc.
Revvity, Inc. (ex Perkinelmer, Inc.) Market Opportunities, M&A and Geo Expansions
In March 2025, Revvity expanded its collaboration with Genomics England to enhance the Generation Study, a pioneering initiative aimed at screening up to 100,000 newborns for over 200 rare genetic disorders. Building upon their existing agreement for DNA extraction services, Revvity will now also provide DNA sequencing, offering an integrated end-to-end solution through its localized laboratory facility in Manchester, UK. This comprehensive approach is designed to accelerate the extraction and sequencing processes, thereby advancing the screening and early diagnosis of rare conditions in newborns. The Generation Study, conducted in partnership with the National Health Service, seeks to inform future decisions on the use of whole genome sequencing in newborn screening, potentially enabling earlier interventions and personalized care for pediatric-onset conditions.
Revvity, Inc. (ex Perkinelmer, Inc.) Risks and Challenges
The healthcare industry is highly regulated, and if it fails to comply with its extensive system of laws and regulations, it could suffer fines and penalties or be required to make significant changes to its operations, which could have a significant adverse effect on the results of its business operations.
Revvity, Inc. (ex Perkinelmer, Inc.) Ecosystem, Partners, Resellers and SI
The Company primarily markets its products and services through a dedicated direct sales force. Utilization of distributors is generally confined to geographic regions where the Company lacks a direct sales presence.
Regarding returns and exchanges, the Company does not offer general return or exchange rights. Exceptions are made solely for defective products covered under the Company's warranty policy. In such cases, the Company may, at its discretion, repair or replace the defective items in accordance with the terms and conditions of the applicable warranty.
Research Methodology
Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.
Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).
For additional information on our methodologies, here's the link:
https://www.appsruntheworld.com/About Ushttps://www.appsruntheworld.com/taxonomy
https://www.appsruntheworld.com/FAQ
